Therapeutic antibodies have revolutionized biopharmaceutical drug development, offering targeted treatments for a range of diseases, from autoimmune disorders to oncology. However, immunogenicity remains a critical hurdle, as the formation of anti-drug antibodies (ADAs) can impact drug efficacy, safety, and regulatory approval.
A recent editorial in Frontiers in Immunology, co-authored by Michael Tovey, an expert in immunogenicity and our chief scientific advisor, examines the latest research on immune responses to therapeutic antibodies.
In this blog post, we will explore the key takeaways and discuss how Svar Life Science's specialized CRO services provide risk mitigation strategies to support biotech and pharmaceutical companies in developing safer, more effective biologics.